Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/25/2022 | $6.00 | Buy | Maxim Group |
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
10-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2024 Financial Results Conference CallDate: March 24, 2025Time: 4:30 p.m. ETLive Call: 1-800
LANGHORNE, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025 on March 25 and 26, 2025. iAccess Alpha Virtual Conference Details:Date: March 25-26, 2025Presentation Day and Time: Tuesday, March 25th at 9:30 a.m. ETWebcast: https://www.webcaster4.com/Webcast/Page/3083/52115 To schedule a one-on-one investor meeting with Mr. Levy, please conta
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2024 Financial Results Conference CallDate: March 24, 2025Time: 4:30 p.m. ETLive Call: 1-800
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2024, after the market close on November 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Third Quarter 2024 Financial Results Conference CallDate: November 13, 2024Time: 4:30 P.M. ETLive Call: 1-800-225-9448 (U.S. Toll Free) or 1-203-518-9708
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e
LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm